(Q36694650)

15 August 2017

Phase II study of neoadjuvant paclitaxel and cisplatin for operable and locally advanced breast cancer: analysis of 126 patients (English)

1 reference

15 August 2017

1 reference

1 reference

A A Ezzat

1

1 reference

15 August 2017

E M Ibrahim

2

1 reference

15 August 2017

D S Ajarim

3

1 reference

15 August 2017

M M Rahal

4

1 reference

15 August 2017

M A Raja

5

1 reference

15 August 2017

A M Tulbah

6

1 reference

15 August 2017

O A Al-Malik

7

1 reference

15 August 2017

M Al-Shabanah

8

1 reference

15 August 2017

R Sorbris

9

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 March 2004

1 reference

British Journal of Cancer

15 August 2017

1 reference

15 August 2017

90

1 reference

15 August 2017

968-974

1 reference

15 August 2017

5

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.bjc.6601616

15 August 2017

0 references

cites work

Salvage chemotherapy with paclitaxel, vinorelbine, and cisplatin (PVC) in anthracycline-resistant advanced breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409621

Vinorelbine and cisplatin (CIVIC regimen) for the treatment of metastatic breast carcinoma after failure of anthracycline- and/or paclitaxel-containing regimens

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409621

Evaluation of survival data and two new rank order statistics arising in its consideration

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409621

Pathological assessment of response to induction chemotherapy in breast cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409621

Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapy

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409621

Primary systemic therapy for operable breast cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409621

A generalization of the probit and logit methods for dose response curves

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409621

Results of treating stage iii carcinoma of the breast by primary radiation therapy

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409621

Paclitaxel-based combination chemotherapy for breast cancer.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409621

Prognostic factors in locally advanced noninflammatory breast cancer. Long-term results following primary chemotherapy

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409621

Natural history and survival of inoperable breast cancer treated with radiotherapy and radiotherapy followed by radical mastectomy

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409621

Maximized reduction of primary breast tumor size using preoperative chemotherapy with doxorubicin and docetaxel.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409621

Nonparametric Estimation from Incomplete Observations

5 September 2018

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FSJ.BJC.6601616

A phase II trial of circadian-timed paclitaxel and cisplatin therapy in metastatic breast cancer

21 January 2018

1 reference

12 December 2020

CARCINOMA OF THE BREAST: II. CRITERIA OF OPERABILITY

1 reference

12 December 2020

Primary chemotherapy in breast cancer

1 reference

12 December 2020

Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute

1 reference

12 December 2020

Primary medical (neo-adjuvant) chemotherapy for operable breast cancer

1 reference

12 December 2020

High complete pathological response in locally advanced breast cancer using paclitaxel and cisplatin

1 reference

12 December 2020

Effect of preoperative chemotherapy on the outcome of women with operable breast cancer

1 reference

12 December 2020

Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18

1 reference

12 December 2020

Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer

1 reference

12 December 2020

Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: preliminary results of a randomised trial: S6

1 reference

12 December 2020

High complete remission rates with primary neoadjuvant infusional chemotherapy for large early breast cancer

1 reference

12 December 2020

Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy

1 reference

12 December 2020

Multimodal treatment for locally advanced breast cancer. Result of chemotherapy-radiotherapy versus chemotherapy-surgery

1 reference

12 December 2020

Identifiers

DOI

10.1038/SJ.BJC.6601616

1 reference

15 August 2017

1 reference

15 August 2017

1 reference